AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12721773 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin formulations stored under class IV conditions (40 degrees C, 75% relative humidity)
Number of subjects: 0
Study 12721773 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclo 50 (Camden) and Dicloflame 50 (Intas) formulations stored under class IV conditions
Number of subjects: 0
Study 12721773 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin formulations stored at ambient conditions
Number of subjects: 0
Study 12721773 — intervention group
Group type: COMPARATOR
Intervention: Diclo 50 (Camden) and Dicloflame 50 (Intas) formulations stored at ambient conditions
Number of subjects: 0
Study 11493735 — intervention group
Group type: EXPERIMENTAL
Intervention: WBC-reduced RBC units
Number of subjects: 1869
Study 9230725 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular anthelminthic treatment with albendazole for 1 year
Number of subjects: 0
Study 9230725 — intervention group
Group type: COMPARATOR
Intervention: Control group (asthmatic subjects without controlled parasitic infections)
Number of subjects: 0
Study 9230725 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular anthelminthic treatment with albendazole
Number of subjects: 0
Study 7495013 — intervention group
Group type: EXPERIMENTAL
Intervention: Triathletes
Number of subjects: 30
Study 7495013 — intervention group
Group type: COMPARATOR
Intervention: Non-triathlete controls
Number of subjects: 30
Study 3629189 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded fundic distension with a balloon to 150 ml
Number of subjects: 13
Study 3629189 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded fundic distension with a balloon to 300 ml
Number of subjects: 13
Study 3629189 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded fundic distension with a balloon to 600 ml
Number of subjects: 13
Study 3629189 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous fundic distension with a volume of 300 ml for 2 1/2 h
Number of subjects: 13
Study 3629189 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticholinergic drug benzilonium bromide during 30 min of fundic distension to 150 ml
Number of subjects: 13
Study 3629189 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin during fundic distension
Number of subjects: 13
Study 29351007 — intervention group
Group type: EXPERIMENTAL
Intervention: Early renal replacement therapy (RRT) initiation strategy
Number of subjects: 619
Study 29351007 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed renal replacement therapy (RRT) initiation strategy
Number of subjects: 619
Study 28103388 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinol (0.1%)
Number of subjects: 16
Study 28103388 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinyl propionate (0.5%)
Number of subjects: 16
Study 28103388 — intervention group
Group type: EXPERIMENTAL
Intervention: Climbazole (0.5%)
Number of subjects: 16
Study 28103388 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose retinol (0.02%) + Climbazole (0.5%)
Number of subjects: 16
Study 28103388 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinol (0.02%) + Climbazole (0.5%)
Number of subjects: 16
Study 28103388 — intervention group
Group type: COMPARATOR
Intervention: Retinyl palmitate
Number of subjects: 16
Study 28103388 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 16
Study 26133126 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavier growth chart (Chart A, n = 686)
Number of subjects: 1295
Study 26133126 — intervention group
Group type: COMPARATOR
Intervention: Lighter growth chart (Chart B, n = 609)
Number of subjects: 1295
Study 26133126 — intervention group
Group type: EXPERIMENTAL
Intervention: Both growth charts
Number of subjects: 1295
Study 23039968 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based intensive counselling group (HBICG)
Number of subjects: 360
Study 23039968 — intervention group
Group type: EXPERIMENTAL
Intervention: Facility-based semi-intensive counselling group (FBSICG)
Number of subjects: 360
Study 23039968 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 360
Study 21570513 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (enox)
Number of subjects: 0
Study 21570513 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab (abx)
Number of subjects: 0
Study 21570513 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 0
Study 21570513 — intervention group
Group type: EXPERIMENTAL
Intervention: Abciximab (abx) combination therapy
Number of subjects: 0
Study 18285668 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir treatment for influenza A
Number of subjects: 299
Study 18285668 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir treatment for influenza B
Number of subjects: 299
Study 18285668 — intervention group
Group type: COMPARATOR
Intervention: Non-treated group for influenza A
Number of subjects: 299
Study 18285668 — intervention group
Group type: COMPARATOR
Intervention: Non-treated group for influenza B
Number of subjects: 299
Study 16866816 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant massage
Number of subjects: 12
Study 16866816 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation and modelling of behaviour with infant
Number of subjects: 12
Study 16866816 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo care
Number of subjects: 12
Study 16866816 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation with child in a preschool programme
Number of subjects: 12
Study 16866816 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion groups
Number of subjects: 12
Study 16866816 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent training programmes
Number of subjects: 12
Study 12967058 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 10 mg/day
Number of subjects: 11
Study 12967058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 11034112 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral melatonin (1 mg)
Number of subjects: 31
Study 11034112 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 9365082 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen
Number of subjects: 20
Study 9365082 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam
Number of subjects: 20
Study 9365082 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen or Piroxicam (responders)
Number of subjects: 20
Study 9365082 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen or Piroxicam (RA patients)
Number of subjects: 20
Study 9365082 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen or Piroxicam (both RA and OA patients)
Number of subjects: 20
Study 9365082 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline ESR and white blood cell counts (RA patients)
Number of subjects: 20
Study 31970414 — intervention group
Group type: EXPERIMENTAL
Intervention: HDAC8 inhibitor
Number of subjects: 0
Study 31970414 — intervention group
Group type: COMPARATOR
Intervention: TGF‐β signaling
Number of subjects: 0
Study 30500133 — intervention group
Group type: EXPERIMENTAL
Intervention: Cook media
Number of subjects: 120
Study 30500133 — intervention group
Group type: COMPARATOR
Intervention: Vitrolife media
Number of subjects: 120
Study 28849629 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 195
Study 28849629 — intervention group
Group type: COMPARATOR
Intervention: Thiazide diuretics
Number of subjects: 195
Study 26304075 — intervention group
Group type: EXPERIMENTAL
Intervention: Anagrelide
Number of subjects: 222
Study 26304075 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyurea
Number of subjects: 222
Study 23617136 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathy intervention (3 weeks, 3 times per week)
Number of subjects: 187
Study 23617136 — intervention group
Group type: COMPARATOR
Intervention: Traction intervention (3 weeks, 3 times per week)
Number of subjects: 187
Study 21211891 — intervention group
Group type: EXPERIMENTAL
Intervention: Open treatment (Class 2b)
Number of subjects: 80
Study 21211891 — intervention group
Group type: COMPARATOR
Intervention: Closed treatment (Class 2a)
Number of subjects: 80
Study 19370950 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxofylline (400mg twice daily)
Number of subjects: 75
Study 19370950 — intervention group
Group type: COMPARATOR
Intervention: Slow release theophylline (400mg once a day at evening)
Number of subjects: 75
Study 15948682 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) combined with porous hydroxyapatite (HA)
Number of subjects: 70
Study 15948682 — intervention group
Group type: COMPARATOR
Intervention: HA with saline (Control)
Number of subjects: 70
Study 12360456 — intervention group
Group type: EXPERIMENTAL
Intervention: Alosetron (1-4 mg twice daily)
Number of subjects: 49
Study 12360456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 10486645 — intervention group
Group type: EXPERIMENTAL
Intervention: Caucasian women (CC)
Number of subjects: 42
Study 10486645 — intervention group
Group type: EXPERIMENTAL
Intervention: Caribbean women (CB)
Number of subjects: 42
Study 10486645 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 42
Study 8735683 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinyloestradiol 50 micrograms
Number of subjects: 8
Study 8735683 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone 10 mg
Number of subjects: 8
Study 1748539 — intervention group
Group type: EXPERIMENTAL
Intervention: labetalol (400 mg to 600 mg per day)
Number of subjects: 30
Study 1748539 — intervention group
Group type: COMPARATOR
Intervention: Control (no drug)
Number of subjects: 30
Study 7097423 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled human milk (true protein 0.8 gm/dl)
Number of subjects: 31
Study 7097423 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted or nonadapted milk formula (protein 1.5 gm/dl)
Number of subjects: 31
Study 7097423 — intervention group
Group type: COMPARATOR
Intervention: Pooled human milk and adapted or nonadapted milk formula
Number of subjects: 31
Study 31990350 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 167
Study 31881066 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized exercise variation (EXP)
Number of subjects: 21
Study 31881066 — intervention group
Group type: COMPARATOR
Intervention: Fixed exercise selection (CON)
Number of subjects: 21
Study 31881066 — intervention group
Group type: EXPERIMENTAL
Intervention: Both EXP and CON
Number of subjects: 21
Study 31881066 — intervention group
Group type: COMPARATOR
Intervention: CON
Number of subjects: 21
Study 28088243 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational workshop addressing sedentary time and diabetes risk
Number of subjects: 71
Study 28088243 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 71
Study 26798966 — intervention group
Group type: EXPERIMENTAL
Intervention: LY900009 at 30 mg
Number of subjects: 35
Study 26798966 — intervention group
Group type: EXPERIMENTAL
Intervention: LY900009 at 15 mg
Number of subjects: 35
Study 24687576 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-warmed intravenous fluids (approximately 41 °C)
Number of subjects: 53
Study 24687576 — intervention group
Group type: COMPARATOR
Intervention: Room temperature intravenous fluids
Number of subjects: 53
Study 22088795 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral stress management (CBSM) intervention for 10 weeks
Number of subjects: 199
Study 22088795 — intervention group
Group type: COMPARATOR
Intervention: Active control condition
Number of subjects: 199
Study 19320679 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate postal treatment for 3 months
Number of subjects: 204
Study 19320679 — intervention group
Group type: COMPARATOR
Intervention: Delayed postal treatment (months 3-6)
Number of subjects: 204
Study 17327244 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention strategies implemented in a community-based HIV/STI prevention trial
Number of subjects: 0
Study 15374763 — intervention group
Group type: EXPERIMENTAL
Intervention: Spoken dialogue modality
Number of subjects: 48
Study 15374763 — intervention group
Group type: COMPARATOR
Intervention: Written dialogue modality
Number of subjects: 48
Study 11150109 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludrocortisone acetate, titrated to 0.1 mg/d (n = 50)
Number of subjects: 100
Study 11150109 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 50)
Number of subjects: 100
Study 9627237 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron (4 mg intravenously)
Number of subjects: 120
Study 9627237 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol (25 microg/kg intravenously)
Number of subjects: 120
Study 9627237 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (placebo)
Number of subjects: 120
Study 7946179 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine at 2.5 mg/day
Number of subjects: 39
Study 7946179 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine at 10 mg/day
Number of subjects: 39
Study 7946179 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine at 10 mg/day + Aspirin at 100 mg/day
Number of subjects: 39
Study 7946179 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine at 2.5 mg/day + Aspirin at 100 mg/day
Number of subjects: 39
Study 3182156 — intervention group
Group type: COMPARATOR
Intervention: Moderate-protein (0.8 g.kg‐1.d‐1), high-carbohydrate hypoenergy diet (MP/HC)
Number of subjects: 19
Study 3182156 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein (1.6 g.kg‐1.d‐1), moderate-carbohydrate hypoenergy diet (HP/MC)
Number of subjects: 19
Study 31311598 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV7 (3 doses)
Number of subjects: 132
Study 31311598 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated
Number of subjects: 132
Study 28162851 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI)
Number of subjects: 6503
Study 28162851 — intervention group
Group type: COMPARATOR
Intervention: Surgical aortic valve replacement (SAVR)
Number of subjects: 6503
Study 28162851 — intervention group
Group type: EXPERIMENTAL
Intervention: RCT subgroup analysis of TAVI
Number of subjects: 6503
Study 28162851 — intervention group
Group type: EXPERIMENTAL
Intervention: PSM subgroup analysis of TAVI
Number of subjects: 6503
Study 26314530 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) treatment
Number of subjects: 0
Study 24013347 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment with accelerated rehabilitation protocol
Number of subjects: 100
Study 24013347 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical treatment
Number of subjects: 100
Study 20813577 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic manipulation (TM)
Number of subjects: 120
Study 20813577 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TM)
Number of subjects: 120
Study 19061152 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose 100 mg t.i.d for 20 weeks
Number of subjects: 20
Study 19061152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 19061152 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20
Study 15964035 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit learning of integrated spatial/stimulus-response sequence
Number of subjects: 0
Study 15964035 — intervention group
Group type: COMPARATOR
Intervention: Implicit learning of spatial sequence
Number of subjects: 0
Study 15964035 — intervention group
Group type: COMPARATOR
Intervention: Implicit learning of stimulus-response sequence
Number of subjects: 0
Study 15964035 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired integrated sequence acquisition
Number of subjects: 0
Study 12866134 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial pacing
Number of subjects: 36
Study 12866134 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone
Number of subjects: 36
Study 12866134 — intervention group
Group type: COMPARATOR
Intervention: Beta-blockers (control)
Number of subjects: 36
Study 10370677 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus high-dose, intermittent IL-2 (2.1 x 10(6) U twice weekly)
Number of subjects: 46
Study 10370677 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus low-dose, continuous IL-2 (7 x 10(5) U daily)
Number of subjects: 46
Study 10370677 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 46
Study 8912507 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (20 mg)
Number of subjects: 19
Study 8912507 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline (25 mg)
Number of subjects: 19
Study 8912507 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Fluoxetine and Amitriptyline
Number of subjects: 19
Study 8912507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 8912507 — intervention group
Group type: EXPERIMENTAL
Intervention: Beck Depression Inventory (BDI) scale
Number of subjects: 19
Study 8912507 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician global VAS
Number of subjects: 19
Study 8912507 — intervention group
Group type: EXPERIMENTAL
Intervention: VAS for fatigue
Number of subjects: 19
Study 8912507 — intervention group
Group type: EXPERIMENTAL
Intervention: VAS for feeling refreshed upon awakening
Number of subjects: 19
Study 8912507 — intervention group
Group type: EXPERIMENTAL
Intervention: Tender point score
Number of subjects: 19
Study 1676832 — intervention group
Group type: EXPERIMENTAL
Intervention: Idazoxan (40 mg tid)
Number of subjects: 9
Study 1676832 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 6859669 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal volume (V(T)) of 14 ml/kg
Number of subjects: 16
Study 6859669 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal volume (V(T)) of 11 ml/kg
Number of subjects: 16
Study 6859669 — intervention group
Group type: EXPERIMENTAL
Intervention: Tidal volume (V(T)) of 7 ml/kg
Number of subjects: 16
Study 6859669 — intervention group
Group type: EXPERIMENTAL
Intervention: High tidal volume (>12 ml/kg)
Number of subjects: 16
Study 6859669 — intervention group
Group type: EXPERIMENTAL
Intervention: High tidal volume
Number of subjects: 16
Study 31251167 — intervention group
Group type: EXPERIMENTAL
Intervention: CRANAPL tool (mean total score 6.4, SD 2.2)
Number of subjects: 120
Study 31251167 — intervention group
Group type: COMPARATOR
Intervention: Notes from academic hospitals (mean score 7.4, SD 2.0 and 6.6, SD 2.1)
Number of subjects: 120
Study 30795490 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 52
Study 30795490 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 52
Study 28264692 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT) provided by a multidisciplinary team
Number of subjects: 210
Study 28264692 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT) provided by a multidisciplinary team and Short Message Service (SMS)
Number of subjects: 210
Study 28264692 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 210
Study 25919473 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular corticosteroid injection
Number of subjects: 122
Study 25919473 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intra-articular and rotator interval injection
Number of subjects: 122
Study 25919473 — intervention group
Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 122
Study 25919473 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular corticosteroid injection and Combined intra-articular/interval injection
Number of subjects: 122
Study 25919473 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcomes (night pain, Shoulder Pain and Disability Index)
Number of subjects: 122
Study 23332183 — intervention group
Group type: EXPERIMENTAL
Intervention: aprotinin
Number of subjects: 35
Study 23332183 — intervention group
Group type: EXPERIMENTAL
Intervention: tranexamic acid
Number of subjects: 35
Study 23332183 — intervention group
Group type: COMPARATOR
Intervention: aprotinin and tranexamic acid
Number of subjects: 35
Study 23332183 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 35
Study 21279511 — intervention group
Group type: EXPERIMENTAL
Intervention: Glutamine (3 g/day)
Number of subjects: 31
Study 21279511 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study 19840637 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 40
Study 19840637 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:50,000 epinephrine
Number of subjects: 40
Study 19840637 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% mepivacaine
Number of subjects: 40
Study 19840637 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 40
Study 17119142 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine gluconate
Number of subjects: 954
Study 17119142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 954
Study 14670578 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional MRI (fMRI) analysis in NF-I participants
Number of subjects: 0
Study 14670578 — intervention group
Group type: COMPARATOR
Intervention: Functional MRI (fMRI) analysis in healthy control participants
Number of subjects: 0
Study 14670578 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral performance on the fMRI task in NF-I participants
Number of subjects: 0
Study 11503993 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-cone technique
Number of subjects: 50
Study 11503993 — intervention group
Group type: EXPERIMENTAL
Intervention: System B
Number of subjects: 50
Study 11503993 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermafil
Number of subjects: 50
Study 11503993 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical condensation
Number of subjects: 50
Study 11503993 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral condensation
Number of subjects: 50
Study 11503993 — intervention group
Group type: EXPERIMENTAL
Intervention: All techniques
Number of subjects: 50